HK1025793A1 - Hepatitis c receptor protein cd81 - Google Patents

Hepatitis c receptor protein cd81

Info

Publication number
HK1025793A1
HK1025793A1 HK00104953.7A HK00104953A HK1025793A1 HK 1025793 A1 HK1025793 A1 HK 1025793A1 HK 00104953 A HK00104953 A HK 00104953A HK 1025793 A1 HK1025793 A1 HK 1025793A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
receptor protein
protein
diagnosis
therapy
Prior art date
Application number
HK00104953.7A
Other languages
English (en)
Inventor
Sergio Abrignani
Guido Grandi
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9721182.5A external-priority patent/GB9721182D0/en
Priority claimed from GBGB9813560.1A external-priority patent/GB9813560D0/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1025793A1 publication Critical patent/HK1025793A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK00104953.7A 1997-10-06 2000-08-09 Hepatitis c receptor protein cd81 HK1025793A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9721182.5A GB9721182D0 (en) 1997-10-06 1997-10-06 Hepatitis C receptor protein
GBGB9813560.1A GB9813560D0 (en) 1998-06-23 1998-06-23 Hepatitis C Receptor Protein
PCT/IB1998/001628 WO1999018198A1 (en) 1997-10-06 1998-10-06 Hepatitis c receptor protein cd81

Publications (1)

Publication Number Publication Date
HK1025793A1 true HK1025793A1 (en) 2000-11-24

Family

ID=26312375

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00104953.7A HK1025793A1 (en) 1997-10-06 2000-08-09 Hepatitis c receptor protein cd81

Country Status (13)

Country Link
US (4) US7097987B2 (da)
EP (1) EP1021534B1 (da)
JP (3) JP4198882B2 (da)
AT (1) ATE449847T1 (da)
AU (1) AU9363398A (da)
CA (1) CA2304796C (da)
CY (1) CY1109868T1 (da)
DE (1) DE69841322D1 (da)
DK (1) DK1021534T3 (da)
ES (1) ES2334727T3 (da)
HK (1) HK1025793A1 (da)
PT (1) PT1021534E (da)
WO (1) WO1999018198A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113914A1 (en) * 2001-12-10 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of CD81 expression
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
WO2001047545A1 (fr) * 1999-12-28 2001-07-05 Sumitomo Pharmaceuticals Company, Limited Produits therapeutiques et prophylactiques pour l'hepatique chronique
WO2001058459A1 (en) * 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedies for hepatitis c
JP2001299140A (ja) * 2000-04-24 2001-10-30 Sumitomo Pharmaceut Co Ltd Ｈｃｖを増幅しうる細胞及び非ヒト動物
GB0016361D0 (en) * 2000-07-03 2000-08-23 Chiron Spa Structure-based HCV drug design
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4221292B2 (ja) * 2001-08-10 2009-02-12 田辺三菱製薬株式会社 Ｃ型肝炎治療薬
DK1662007T3 (da) * 2003-08-28 2011-06-14 Dainippon Sumitomo Pharma Co Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
NL2001318C2 (nl) 2008-02-25 2009-08-26 Schuitemaker Mach Bv Inrichting en werkwijze voor het snijden van kuilvoer.
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2803673A4 (en) 2011-12-26 2016-03-23 Shionogi & Co MONOCLONAL ANTIBODY FOR THE DETECTION OF EXOSOMES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341629C (en) 1987-11-18 2012-05-08 Chiron Corporation Hepatitis c diagnostics and vaccines
US5631407A (en) * 1989-03-10 1997-05-20 The Trustees Of Columbia University In The City Of New York Transgenic mouse expressing DNA sequences encoding the human poliovirus receptor
UA50829C2 (uk) 1989-03-17 2002-11-15 Чірон Корпорейшн Очищений поліпептид, що містить антиген вірусу гепатиту с, полінуклеотид, вектор, клітини, система експресії, моноклональне антитіло, препарат поліклональних антитіл, нуклеотидна проба, аналітичні набори, спосіб виявлення нуклеїнових кислот, способи імуноаналізу, вакцина, спосіб одержання антитіл
WO1991007489A1 (en) * 1989-11-22 1991-05-30 Childrens Hospital Of Los Angeles Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US6031088A (en) * 1996-05-23 2000-02-29 Albert Einstein College Of Medicine Of Yeshiva University Polycystic kidney disease PKD2 gene and uses thereof
US7491865B2 (en) * 2004-08-19 2009-02-17 Fred Hutchinson Cancer Research Center Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene

Also Published As

Publication number Publication date
US7097987B2 (en) 2006-08-29
CY1109868T1 (el) 2014-09-10
US20120066779A1 (en) 2012-03-15
JP2012125246A (ja) 2012-07-05
JP2001519150A (ja) 2001-10-23
JP2009035553A (ja) 2009-02-19
JP4198882B2 (ja) 2008-12-17
EP1021534B1 (en) 2009-11-25
ES2334727T3 (es) 2010-03-15
WO1999018198A1 (en) 1999-04-15
AU9363398A (en) 1999-04-27
US20070087407A1 (en) 2007-04-19
CA2304796C (en) 2013-12-03
US20090025098A1 (en) 2009-01-22
US20040258694A1 (en) 2004-12-23
PT1021534E (pt) 2010-03-03
DK1021534T3 (da) 2010-02-01
EP1021534A1 (en) 2000-07-26
ATE449847T1 (de) 2009-12-15
CA2304796A1 (en) 1999-04-15
DE69841322D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
DE60033649D1 (de) Verbindungen und therapeutische methoden
MXPA02008239A (es) Gen humano de la esquizofrenia.
TR200100637T2 (tr) Yeni doğal ürün türevleri
PL340465A1 (en) Antibodies against phosphorylated vasp (vasodilating agent stimulated phosphoprotein) hybridom cells for obtaining them and their application
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
PT1196188E (pt) Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
DE59911103D1 (de) ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1)
GB9723630D0 (en) M.vaccae preparation and its use
EP1878795A3 (en) Compositions and methods for the treatment of immune related diseases
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151006